NANOVIRICIDES, INC. — Form 8-K
Filed September 29, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
NanoViricides extended employment agreements for two key executives effective July 1, 2026 through June 30, 2027. CEO Anil R. Diwan receives $400,000 base salary, fringe benefits, and 10,204 Series A Convertible Preferred Shares (vesting quarterly over 12 months, with 25% vesting per quarter). CFO Meeta Vyas' extension terms were not detailed in the filing excerpt. Both agreements are renewable annually by Board approval and terminable by either party with 30 days' notice.
Why this rating
Routine executive contract extensions; $400K salary and share grants represent standard executive comp retention, immaterial relative to $23.7M market cap.
See more from September 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.